Humanoid robotics moved from concept videos to factory floors over the past 18 months, and three ETFs now offer materially different ways to play it: Themes Humanoid Robotics ETF (NASDAQ:BOTT), ROBO Global Robotics and Automation Index ETF (NYSEARCA:ROBO), and the Global X Robotics & Artificial Intelligence ETF (NASDAQ:BOTZ). Each captures the theme from a different angle, and only one is a true pure-play on the Tesla Optimus and Figure AI commercialization curve.
BOTT is the newest and narrowest, launched in 2024 as the only pure-play humanoid ETF. ROBO has been the legacy industrial robotics fund since 2013. BOTZ sits in between, anchored by automation giants but quietly accumulating positions in the Korean and Chinese humanoid names that most U.S. investors have never opened a brokerage tab for.
The humanoid commercialization curve
The investable thesis stopped being speculative when humanoid units started showing up on payrolls. Tesla is ramping Optimus production, Figure is rolling out Figure 02 in commercial deployments, and Apptronik units are working alongside humans in Mercedes plants. The picks-and-shovels layer, AI chips, vision sensors, actuators, and industrial automation backbones, is already generating revenue regardless of whether any single humanoid platform wins.
That split matters for ETF selection. A fund concentrated on the platform builders captures the upside if humanoids scale; a fund anchored in the enablers captures revenue today whether Optimus ships at 10,000 units or 1 million. The three funds below sit at different points on that spectrum.
BOTT: the only pure-play in the category
BOTT exists for one reason: there was no clean way to buy the humanoid theme as a single ticker until Themes ETFs launched it. The fund holds Tesla, Figure AI suppliers, and Boston Dynamics-adjacent names, which is the actual composition investors want when they search for “humanoid robotics ETF” and instead find that older robotics funds have a 10% weighting in chip equipment makers.
The performance tells the story of how concentrated this exposure really is. BOTT is up roughly 35% year-to-date and has more than doubled over the past year, with shares trading around $56. That is the kind of return profile that comes from owning a small basket of names tied directly to a single narrative, not a diversified portfolio.
The tradeoff is structural. BOTT is small, new, and concentrated. Liquidity is thinner than the legacy robotics funds, and the holdings overlap heavily with names that have already run hard on Optimus and Figure milestones. A delay in commercial humanoid deployment, or a single bad quarter from Tesla, would land harder here than in any other fund in the category. Investors choosing BOTT are buying the thesis in its purest form, which means accepting that the fund will trade like a leveraged bet on humanoid milestones.
BOTZ: the overlooked humanoid backdoor through Asia
BOTZ markets itself as a broad robotics and AI fund, but its underlying holdings make it relevant to the humanoid theme. Underneath the headline weightings sit positions that most U.S. investors would never assemble on their own: Rainbow Robotics at roughly 4%, Ubtech Robotics at near 2%, Doosan Robotics at around 2%, and ROBOTIS at just under 1%. Rainbow and Doosan are Korean humanoid developers; Ubtech is one of the most advanced Chinese manufacturers of humanoid robots. Direct U.S. retail access to those names is awkward at best.
The fund pairs that emerging-markets humanoid exposure with the industrial automation companies whose actuators, harmonic drives, and servo motors end up inside every humanoid platform. ABB is near 11%, FANUC near 10%, Keyence near 6%, and SMC Corporation near 5%. Add NVIDIA near 10% for the AI compute layer, and the portfolio captures the full humanoid supply stack rather than just the brand names on the chest plates.
BOTZ is also the institutional-scale option in this group, with net assets of roughly $3.5 billion across 48 positions. That scale brings tighter spreads and easier position sizing. Performance has been more measured, up about 13% year to date and 35% over the past year, with shares near $40, reflecting the drag from the slower-moving industrial names that balance out the humanoid pure-plays.
The tradeoff: BOTZ is not going to move like BOTT on a Figure AI funding round or an Optimus production update. Industrial automation, cyclicality, and Japanese yen exposure are real factors. Investors get diversified humanoid exposure with less narrative torque.
ROBO: the legacy diversified robotics fund
ROBO is the oldest fund in the category and the least humanoid-specific of the three. The top weightings make that clear: Intel near 9%, Advantest around 6%, AMD around 6%, KLA near 4%, and ABB near 4%. Those are semiconductor design and test names, not humanoid builders. The fund’s index methodology is equal-weighted across the broader automation ecosystem, so chip equipment and factory automation crowd out the pure humanoid plays.
The investment logic for including ROBO is the picks-and-shovels argument. Every humanoid platform needs AI training chips, vision sensors, and semiconductor inspection equipment to build the silicon that runs them. Teradyne near 4% and Rockwell Automation around 3% round out an exposure profile that benefits whether Optimus, Figure, or a name not yet public ends up dominating.
Performance: up roughly 30% year to date and 63% over the past year, with shares near $88. Expense ratio is 0.4%, which is competitive for a thematic fund of this depth. The tradeoff is dilution: investors looking for direct humanoid exposure will find ROBO behaves more like a diversified industrial-tech fund than a humanoid play. Single humanoid milestones rarely move the needle on a portfolio this broad.
Choosing between the three
The decision framework comes down to how much narrative concentration an investor wants. BOTT is the cleanest expression of the humanoid thesis and the fund that will move the most on Optimus and Figure milestones, in either direction. It suits investors who already believe humanoids will commercialize within the decade and want exposure that reflects that conviction.
BOTZ is the option for investors who want exposure to humanoid technology without betting the position on Tesla. The Korean and Chinese humanoid holdings provide hard-to-replicate access, and the industrial automation core dampens the volatility that BOTT carries.
ROBO is the choice for investors seeking exposure to the broader automation supply chain that benefits from humanoid adoption without relying on it. It is the least humanoid of the three and the most diversified, which is a feature for some allocators and a bug for others.
Top Gaining Stocks
Top Losing Stocks